New Drug Development

Written By 3B Digital

Composition:

Chair: Pablo Berlanga (France) pablo.berlanga@gustaveroussy.fr
Vice chair: Angelika Eggert (Germany) angelika.eggert@charite.de

Members:

  • Matthias Fischer (Germany)

  • Anette Kunkele (Germany)

  • Cormac Owens (Ireland)

  • Jan Molenaar (The Netherlands)

  • Louis Chesler (United Kingdom)

Aims

  • Be recognised as conduit for NBL NDD in Europe

  • Organise membership of NDD

  • Formalise links with COG/NANT (and others)

  • Drive preclinical NBL testing in Europe

  • Deliver on set up of X number of new trials

  • Influence front-line strategy

  • Work with the relapsed NB strategy working group to set up and deliver first relapse trial(s) in SIOPEN

  • Develop links with industry, particularly small biotechs interested in childhood cancers, as well as regulators

Interested in joining the Specialty committee?

Please first register to become a SIOPEN member and then contact the specialty committee chair and/or co-chair in order to join the committee.

3B Digital https://www.3bweb.com
Previous

Immunotherapy
Next

Nuclear medicine and physics